Molecular Pathways: HER3 Targeted TherapyGALA, Kinisha; CHANDARLAPATY, Sarat.Clinical cancer research (Print). 2014, Vol 20, Num 6, pp 1410-1416, issn 1078-0432, 7 p.Article

HER³ Is a Determinant for Poor Prognosis in MelanomaRESCHKE, Markus; MIHIC-PROBST, Daniela; HTUN VAN DER HORST, Edward et al.Clinical cancer research (Print). 2008, Vol 14, Num 16, pp 5188-5197, issn 1078-0432, 10 p.Article

RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector ActivationMIRSCHBERGER, Christian; SCHILLER, Christian B; HOPFNER, Karl-Peter et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 16, pp 5183-5194, issn 0008-5472, 12 p.Article

HER3 Overexpression as an Independent Indicator of Poor Prognosis for Patients with Curatively Resected Pancreatic CancerHIRAKAWA, Toshiki; NAKATA, Bunzo; AMANO, Ryosuke et al.Oncology. 2011, Vol 81, Num 3-4, pp 192-198, issn 0030-2414, 7 p.Article

An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or NeuregulinGARNER, Andrew P; BIALUCHA, Carl U; YAN CHEN et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 19, pp 6024-6035, issn 0008-5472, 12 p.Article

HER3 Overexpression and Survival in Solid Tumors: A Meta-analysisOCANA, Alberto; VERA-BADILLO, Francisco; SERUGA, Bostjan et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 4, pp 266-273, issn 0027-8874, 8 p.Article

The upgraded role of HER3 and HER4 receptors in breast cancerKOUTRAS, Angelos K; FOUNTZILAS, George; KALOGERAS, Konstantine T et al.Critical reviews in oncology/hematology. 2010, Vol 74, Num 2, pp 73-78, issn 1040-8428, 6 p.Article

Increasing Potential of HER3 Signaling in Colon Cancer Progression and TherapyGESPACH, Christian.Clinical cancer research (Print). 2012, Vol 18, Num 4, pp 917-919, issn 1078-0432, 3 p.Article

Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 FunctionGARRETT, Joan T; SUTTON, Cammie R; GABRIELA KUBA, Maria et al.Clinical cancer research (Print). 2013, Vol 19, Num 3, pp 610-619, issn 1078-0432, 10 p.Article

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and RadiationHUANG, Shyhmin; CHUNRONG LI; ARMSTRONG, Eric A et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 2, pp 824-833, issn 0008-5472, 10 p.Article

Preclinical pharmacokinetics of MEHD7945A, a novel EGFR/ HER3 dual-action antibody, and prediction of its human pharmacokinetics and efficacious clinical doseKAMATH, Amrita V; DAN LU; DAMICO-BEYER, Lisa A et al.Cancer chemotherapy and pharmacology. 2012, Vol 69, Num 4, pp 1063-1069, issn 0344-5704, 7 p.Article

HER3 Expression in Cutaneous TumorsWIMMER, Eva; KRAEHN-SENFTLEBEN, Gertraud; ISSING, Wolfgang J et al.Anticancer research. 2008, Vol 28, Num 2A, pp 973-979, issn 0250-7005, 7 p.Article

Toward the Prognostic Significance and Therapeutic Potential of HER3 Receptor Tyrosine Kinase in Human Colon CancerBEJI, Abdelhamid; HORST, David; ENGEL, Jutta et al.Clinical cancer research (Print). 2012, Vol 18, Num 4, pp 956-968, issn 1078-0432, 13 p.Article

microRNA-205 Regulates HER3 in Human Breast CancerLORIO, Marilena V; CASALINI, Patrizia; PIOVAN, Claudia et al.Cancer research (Chicago, Ill.). 2009, Vol 69, Num 6, pp 2195-2200, issn 0008-5472, 6 p.Article

Engineering and characterization of a bispecific HER2 x EGFR-binding affibody moleculeFRIEDMAN, Mikaela; LINDSTRÖM, Sara; EKERLJUNG, Lina et al.Biotechnology and applied biochemistry. 2009, Vol 54, pp 121-131, issn 0885-4513, 11 p., 2Article

Role for HER2/neu and HER3 in fulvestrant-resistant breast cancerOSIPO, Clodia; MEEKE, Kathleen; DONG CHENG et al.International journal of oncology. 2007, Vol 30, Num 2, pp 509-520, issn 1019-6439, 12 p.Article

Neuregulin Autocrine Signaling Promotes Self-Renewal of Breast Tumor-Initiating Cells by Triggering HER2/HER3 ActivationLEE, Cleo Yi-Fang; YUAN LIN; BRATMAN, Scott V et al.Cancer research (Chicago, Ill.). 2014, Vol 74, Num 1, pp 341-352, issn 0008-5472, 12 p.Article

Compensatory ErbB3/c-Src signaling enhances carcinoma cell survival to ionizing radiationCONTESSA, Joseph N; ABELL, Angela; MIKKELSEN, Ross B et al.Breast cancer research and treatment. 2006, Vol 95, Num 1, pp 17-27, issn 0167-6806, 11 p.Article

Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast CancersGARRETT, Joan T; SUTTON, Cammie R; KURUPI, Richard et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 19, pp 6013-6023, issn 0008-5472, 11 p.Article

HER3, serious partner in crime. Therapeutic approaches and potential biomarkers for effect of HER3-targetingKOL, Arjan; VAN SCHELTINGA, Anton G. T. Terwisscha; TIMMER-BOSSCHA, Hetty et al.Pharmacology & therapeutics (Oxford). 2014, Vol 143, Num 1, pp 1-11, issn 0163-7258, 11 p.Article

HER3 status by immunohistochemistry is correlated with poor prognosis in hormone receptor-negative breast cancer patientsSOO YOUN BAE; YOON LA CHOI; SEOK JIN NAM et al.Breast cancer research and treatment. 2013, Vol 139, Num 3, pp 741-750, issn 0167-6806, 10 p.Article

Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathwaySAKAI, Kazuko; YOKOTE, Hideyuki; MURAKAMI-MUROFUSHI, Kimiko et al.Cancer science. 2007, Vol 98, Num 9, pp 1498-1503, issn 1347-9032, 6 p.Article

Epidermal growth factor receptor changes during breast cancer metastasisFUCHS, Ilka B; SIEMER, Ildiko; BOHLER, Helmut et al.Anticancer research. 2006, Vol 26, Num 6B, pp 4397-4401, issn 0250-7005, 5 p.Article

HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancerLIPTON, Allan; GOODMAN, Laurie; NEWTON, Alicia et al.Breast cancer research and treatment. 2013, Vol 141, Num 1, pp 43-53, issn 0167-6806, 11 p.Article

Involvement of Heregulin/HER3 in the Primary Culture of Human Urothelial CancerOKUYAMA, Hiroaki; YOSHIDA, Takahiro; ENDO, Hiroko et al.The Journal of urology. 2013, Vol 190, Num 1, pp 302-310, issn 0022-5347, 9 p.Article